Abstract
The endogenous steroid 2-methoxyestradiol (2-ME) is a metabolite of 17-estradiol and its biosynthesis is well established. Moreover, 2-ME is also biosynthesized from estrone. For several years, 2-ME was perceived as an inactive metabolite devoid of any interesting biological activities. Since the late 1980s, a number of biological and pharmacological studies have revealed that 2-ME possesses interesting anti-cancer effects without any undesirable estrogen activity. In particular, the anti-vascular effects and anti-angiogenic activities that 2-ME exhibit, are of great interest and importance, in view of the development of new anti-cancer drugs based on 2-ME. Several clinical trial development programs have been initiated using the steroid 2-ME. In addition, based on the many pharmacological activities reported for 2-ME, but also due to the general interest in total and semi-synthesis of endogenous steroids, several research groups working with organic synthesis have prepared this steroid. Herein, the anti-cancer effects, the results from the clinical trial development programs and the synthetic studies towards 2-ME, are reviewed.
Keywords: Steroid, 2-methoxyestradiol, anti-cancer effects, anti-vascular effects, anti-angiogenic activities, tubulin inhibition, clinical trials, total synthesis, regioselectivity.
Current Pharmaceutical Design
Title:Synthesis and Pharmacological Effects of the Anti-Cancer Agent 2-Methoxyestradiol
Volume: 21 Issue: 38
Author(s): Eirik Johansson Solum, Oyvind W. Akselsen, Anders Vik and Trond Vidar Hansen
Affiliation:
Keywords: Steroid, 2-methoxyestradiol, anti-cancer effects, anti-vascular effects, anti-angiogenic activities, tubulin inhibition, clinical trials, total synthesis, regioselectivity.
Abstract: The endogenous steroid 2-methoxyestradiol (2-ME) is a metabolite of 17-estradiol and its biosynthesis is well established. Moreover, 2-ME is also biosynthesized from estrone. For several years, 2-ME was perceived as an inactive metabolite devoid of any interesting biological activities. Since the late 1980s, a number of biological and pharmacological studies have revealed that 2-ME possesses interesting anti-cancer effects without any undesirable estrogen activity. In particular, the anti-vascular effects and anti-angiogenic activities that 2-ME exhibit, are of great interest and importance, in view of the development of new anti-cancer drugs based on 2-ME. Several clinical trial development programs have been initiated using the steroid 2-ME. In addition, based on the many pharmacological activities reported for 2-ME, but also due to the general interest in total and semi-synthesis of endogenous steroids, several research groups working with organic synthesis have prepared this steroid. Herein, the anti-cancer effects, the results from the clinical trial development programs and the synthetic studies towards 2-ME, are reviewed.
Export Options
About this article
Cite this article as:
Solum Johansson Eirik, Akselsen W. Oyvind, Vik Anders and Hansen Vidar Trond, Synthesis and Pharmacological Effects of the Anti-Cancer Agent 2-Methoxyestradiol, Current Pharmaceutical Design 2015; 21 (38) . https://dx.doi.org/10.2174/1381612821666151002112511
DOI https://dx.doi.org/10.2174/1381612821666151002112511 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Intracellular Logistics of BST-2/Tetherin
Current HIV Research Heterocyclic Compounds as Anti-Inflammatory Agents
Current Bioactive Compounds Recent Advances in Phenanthroindolizidine and Phenanthroquinolizidine Derivatives with Anticancer Activities
Anti-Cancer Agents in Medicinal Chemistry Preventive and Therapeutic Effects of the Retinoid X Receptor Agonist Bexarotene on Tumors
Current Drug Metabolism Cyclin D1 Gene Silencing by siRNA in Ex Vivo Human Tissue Cultures
Current Drug Delivery Ozone Dosage Effect on C6 Cell Growth: in Vitro and in Vivo Tests
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Current Drug Targets A Novel Treatment Strategy for Sepsis and Septic Shock Based on the Interactions between Prostanoids, Nitric Oxide, and 20-Hydroxyeicosatetraenoic Acid
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Essential Fatty Acids - A Review
Current Pharmaceutical Biotechnology Recent Advances of Silver Nanoparticles in Cancer Diagnosis and Treatment
Anti-Cancer Agents in Medicinal Chemistry Azathioprine, Mucosal Healing in Ulcerative Colitis, and the Chemoprevention of Colitic Cancer: A Clinical-Practice-Based Forecast
Inflammation & Allergy - Drug Targets (Discontinued) Armed Oncolytic Adenoviruses and Polymer-shielded Nanocomplex for Systemic Delivery
Current Cancer Therapy Reviews Treatment of Psoriasis: A Comprehensive Review of Entire Therapies
Current Drug Safety Vitamin-D in the Immune System: Genomic and Non-Genomic Actions
Mini-Reviews in Medicinal Chemistry Distinguished Photons: A Review of In Vivo Spectral Fluorescence Imaging in Small Animals
Current Pharmaceutical Biotechnology Current Opinion in the Pharmaceutical Management of Irritable and Inflammatory Bowel Diseases: Role of ATP
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Characterization of Gemcitabine Loaded Polyhydroxybutyrate Coated Magnetic Nanoparticles for Targeted Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry In vitro effects of infrared A radiation on the synthesis of MMP-1, catalase, superoxide dismutase and GADD45 alpha protein
Inflammation & Allergy - Drug Targets (Discontinued) Anti-Epidermal Growth Factor Receptor Strategies to Enhance Radiation Action
Current Medicinal Chemistry - Anti-Cancer Agents Possible Selective Cytotoxicity of Vanadium Complex on Breast Cancer Cells Involving Pathophysiological Pathways
Anti-Cancer Agents in Medicinal Chemistry